The underlying mechanism may involve its targeting on Syk to upregulate the PKCθ/mTOR ratio during the active phase of RA, and to downregulate the PKCθ/mTOR ratio during the inactive phase, ultimately promoting Treg-dependent tolerance restoration. The gene discussed is MTOR; the disease is rheumatoid arthritis.